Bexarotene is a member of the retinoid class of drugs that is associated with birth defects in humans.
Caused birth defects when administered orally to pregnant rats.
Must not be administered to a pregnant woman.
Monitoring data
Negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within one week prior to therapy. Repeat pregnancy test at monthly intervals during therapy
Effective contraception used for 1 month prior to initiation of therapy, during therapy and > 1 month after drug discontinued.